NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PVLA

Palvella Therapeutics Inc

Jun 30 • 04:00PM ET

22.54

Dollar change +0.46
Percentage change 2.08	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT AGEN ADAP BLUE KURA FATE MRNA NVAX CRSP SGMO

| Held by: IWM VXF IWO IWC AVSC SBIO RSSL UWM URTY OMFS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.61	Insider Own	40.80%	Shs Outstand	11.02M	Perf Week	0.00%
Market Cap	249.20M	Forward P/E	-	EPS next Y	-3.23	Insider Trans	0.11%	Shs Float	6.55M	Perf Month	-9.04%
Enterprise Value	173.57M	PEG	-	EPS next Q	-0.74	Inst Own	30.26%	Short Float	5.91%	Perf Quarter	-19.79%
Income	-15.95M	P/S	184.59	EPS this Y	61.97%	Inst Trans	59.75%	Short Ratio	4.01	Perf Half Y	91.02%
Sales	1.35M	P/B	4.47	EPS next Y	-8.62%	ROA	-39.93%	Short Interest	0.39M	Perf YTD	87.83%
Book/sh	5.04	P/C	3.29	EPS next 5Y	18.74%	ROE	-68.21%	52W High	29.27 -22.99%	Perf Year	158.49%
Cash/sh	6.84	P/FCF	-	EPS past 3/5Y	48.30% 29.42%	ROIC	-28.70%	52W Low	6.20 263.55%	Perf 3Y	-84.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.27% 8.30%	Perf 5Y	-91.38%
Dividend TTM	-	EV/Sales	128.57	EPS Y/Y TTM	54.84%	Oper. Margin	-1338.54%	ATR (14)	1.89	Perf 10Y	-92.96%
Dividend Ex-Date	-	Quick Ratio	8.84	Sales Y/Y TTM	-97.15%	Profit Margin	-1179.96%	RSI (14)	47.96	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.84	EPS Q/Q	79.95%	SMA20	-4.15%	Beta	-0.11	Target Price	49.22
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	-4.45%	Rel Volume	0.77	Prev Close	22.08
Employees	14	LT Debt/Eq	0.00	Earnings	May 15 BMO	SMA200	17.06%	Avg Volume	96.54K	Price	22.54
IPO	Jan 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	38.91% -	Trades		Volume	74,453	Change	2.08%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-25	Initiated	Chardan Capital Markets	Buy	$50
Mar-26-25	Initiated	Stifel	Buy	$45
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Feb-20-25	Initiated	Canaccord Genuity	Buy	$39
Feb-05-25	Initiated	TD Cowen	Buy	$44
Dec-26-24	Initiated	H.C. Wainwright	Buy	$38
Dec-18-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform	$5
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform	$5
Mar-19-18	Initiated	Jefferies	Buy	$12
Mar-19-18	Initiated	Evercore ISI	Outperform	$13
Jan-16-18	Reiterated	H.C. Wainwright	Buy	$9 → $12
May-30-17	Initiated	Rodman & Renshaw	Buy	$9
Aug-05-16	Resumed	ROTH Capital	Buy
Aug-12-15	Initiated	JMP Securities	Mkt Outperform
Jul-27-15	Initiated	Oppenheimer	Outperform	$8
Jul-22-15	Initiated	ROTH Capital	Buy	$7

Show Previous Ratings

Today 07:30AM	Palvella Therapeutics Added to Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-23-25 07:30AM	Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% (GlobeNewswire)
Jun-18-25 07:30AM	Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors (GlobeNewswire)
Jun-09-25 07:30AM	Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations (GlobeNewswire)
May-27-25 08:00AM	Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer (GlobeNewswire)
03:09AM	Loading…
May-16-25 03:09AM	Palvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ... (GuruFocus.com)
May-15-25 07:30AM	Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-25 07:30AM	Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
May-05-25 07:30AM	Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 (GlobeNewswire)
Apr-30-25 05:44AM	Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025 (Insider Monkey)
Apr-23-25 04:15PM	Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology (GlobeNewswire)
Apr-22-25 07:30AM	Palvella Therapeutics Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations (GlobeNewswire) +5.74%
Apr-11-25 07:30AM	Palvella Therapeutics Announces QTORIN Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology (GlobeNewswire) +9.51%
Apr-04-25 08:00AM	Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
Apr-02-25 08:00AM	Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology (GlobeNewswire) +14.33%
12:52PM	Loading…
Apr-01-25 12:52PM	Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? (Insider Monkey) -15.72%
03:01AM	Palvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Mar-31-25 07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-27-25 09:50AM	Is Palvella Therapeutics (PVLA) the Best Performing Stock So Far in 2025? (InsiderMonkey)
Mar-18-25 08:30AM	Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 (GlobeNewswire)
Mar-01-25 05:30PM	Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-25-25 08:00AM	Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference (GlobeNewswire)
Feb-21-25 09:35AM	Palantir initiated, Roku upgraded: Wall Streets top analyst calls (TipRanks)
Feb-10-25 08:00AM	Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old (GlobeNewswire)
Jan-10-25 08:00AM	Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies (GlobeNewswire)
Jan-08-25 08:00AM	Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Cutaneous Venous Malformations (GlobeNewswire)
Dec-27-24 06:20AM	Palvella Therapeutics initiated with a Buy at H.C. Wainwright (TipRanks)
Nov-13-24 04:53PM	Pieris Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
Nov-07-24 08:30AM	Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Microcystic Lymphatic Malformations (GlobeNewswire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
07:30AM	Loading…
Oct-15-24 07:30AM	Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference (GlobeNewswire)
Oct-03-24 07:30AM	Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations (GlobeNewswire)
Aug-14-24 07:11PM	Pieris Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE) +88.60%
Jul-08-24 08:15AM	Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors (GlobeNewswire) -10.60%
May-17-24 02:52PM	PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
May-15-24 05:43PM	Pieris Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
Apr-19-24 12:10PM	Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split (ACCESSWIRE) -6.60%
Mar-27-24 08:00AM	Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential (ACCESSWIRE)
Nov-14-23 05:36PM	Pieris Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -7.36%
Sep-25-23 12:00PM	Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why (Zacks)
Aug-24-23 12:32PM	Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis (GuruFocus.com)
Aug-23-23 12:00PM	Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +19.68%
Aug-17-23 08:00AM	Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific (ACCESSWIRE) +8.06%
Jul-19-23 02:02PM	Pieris lays off most staff after AstraZeneca pulls out of partnership (American City Business Journals)
08:40AM	Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises (Zacks)
Jul-18-23 01:59PM	Why Pieris Pharmaceuticals Shares Shooting Higher Today? (Benzinga) +11.81%
09:15AM	Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring (ACCESSWIRE)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace)
Jun-23-23 10:50AM	Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate (Zacks) +12.02%
Jun-21-23 07:00AM	Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study (ACCESSWIRE) -70.86%
Jun-11-23 10:28AM	We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate (Simply Wall St.)
Jun-02-23 04:30PM	Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference (ACCESSWIRE) +5.35%
May-22-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference (ACCESSWIRE) +6.00%
May-21-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference (ACCESSWIRE)
May-15-23 06:07AM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 01:41PM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript (Insider Monkey) +10.60%
May-10-23 08:15AM	Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates (ACCESSWIRE)
May-05-23 06:41AM	Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +7.42%
May-04-23 08:00AM	Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) (ACCESSWIRE)
May-02-23 04:30PM	Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023 (ACCESSWIRE) +5.90%
Apr-17-23 08:00AM	Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting (ACCESSWIRE) +14.89%
Apr-01-23 12:47PM	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:10AM	Pieris Pharmaceuticals Full Year 2022 Earnings: US$0.45 loss per share (vs US$0.71 loss in FY 2021) (Simply Wall St.) -5.24%
Mar-29-23 05:00PM	Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively (Benzinga) -28.38%
08:35AM	Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates (ACCESSWIRE)
Mar-24-23 05:00PM	Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023 (ACCESSWIRE)
Feb-19-23 07:39AM	Pieris Pharmaceuticals (NASDAQ:PIRS) shareholders have endured a 81% loss from investing in the stock five years ago (Simply Wall St.)
Feb-14-23 05:40AM	Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains? (Zacks)
Jan-17-23 07:10AM	While institutions own 32% of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), individual investors are its largest shareholders with 40% ownership (Simply Wall St.) -16.67%
Jan-10-23 08:00AM	Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346) (ACCESSWIRE) +10.16%
Dec-21-22 06:01AM	Companies Like Pieris Pharmaceuticals (NASDAQ:PIRS) Could Be Quite Risky (Simply Wall St.)
Nov-23-22 08:00AM	Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference (ACCESSWIRE) +6.26%
Nov-09-22 08:00AM	Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference (ACCESSWIRE) -7.30%
Nov-02-22 08:35AM	Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-01-22 09:15AM	Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220 (ACCESSWIRE)
Oct-26-22 08:00AM	Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022 (ACCESSWIRE)
Sep-12-22 08:03AM	Shareholders in Pieris Pharmaceuticals (NASDAQ:PIRS) are in the red if they invested a year ago (Simply Wall St.)
Sep-08-22 04:01PM	Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE)
Aug-24-22 10:34AM	Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate (Benzinga) +5.33%
08:00AM	Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS (ACCESSWIRE)
Aug-10-22 06:20AM	One Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analyst Is Reducing Their Forecasts For This Year (Simply Wall St.)
Aug-04-22 02:03PM	Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs (Benzinga) -5.49%
09:35AM	Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-28-22 07:20AM	Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022 (ACCESSWIRE)
Jul-14-22 06:29AM	Here's Why We're Not Too Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Situation (Simply Wall St.)
Jun-02-22 08:00AM	Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference (ACCESSWIRE)
May-18-22 09:35AM	Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:00AM	Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference (ACCESSWIRE)
May-16-22 09:35AM	After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS) (Zacks)
08:29AM	How Many Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Shares Do Institutions Own? (Simply Wall St.)
May-11-22 08:45AM	Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -20.44%
07:00AM	Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-04-22 08:00AM	Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022 (ACCESSWIRE)
Apr-15-22 11:00AM	3 Risky Stocks With Huge Potential Upside (Motley Fool)
Apr-09-22 06:00AM	This Pharmaceutical Stock Could Be Your Lottery Ticket (Motley Fool)

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JENKINS GEORGE M	Director	Apr 09 '25	Buy	20.27	2,490	50,472	13,516	Apr 10 07:06 PM
JENKINS GEORGE M	Director	Apr 09 '25	Buy	20.13	2,500	50,325	183,171	Apr 10 07:06 PM
JENKINS GEORGE M	Director	Dec 18 '24	Buy	12.93	4,000	51,720	180,671	Dec 19 10:23 AM
GERAGHTY JAMES A	Director	Aug 07 '24	Buy	1.00	1	1	1	Oct 28 05:18 PM
ADAR1 Capital Management, LLC	10% Owner	Aug 12 '24	Buy	15.88	3,000	47,647	129,574	Aug 12 06:48 PM
ADAR1 Capital Management, LLC	10% Owner	Aug 09 '24	Buy	14.89	3,000	44,679	127,331	Aug 12 06:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PVLA

Palvella Therapeutics Inc

Upgrade your FINVIZ experience